Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX
Market Cap: 440.4B GBX

Operating Margin
Dechra Pharmaceuticals PLC

3.3%
Current
12%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.3%
=
Operating Profit
24.9m
/
Revenue
761.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
258.9B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
208.7B GBP
24%
CH
Novartis AG
SIX:NOVN
207.7B CHF
33%
US
Merck & Co Inc
NYSE:MRK
264.8B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143.2B USD
29%
FR
Sanofi SA
PAR:SAN
99.3B EUR
24%
No Stocks Found

Dechra Pharmaceuticals PLC
Glance View

Market Cap
440.4B GBX
Industry
Pharmaceuticals

Dechra Pharmaceuticals PLC has carved out its niche in the veterinary pharmaceuticals industry, focusing on animal health, which is a sector often less spotlighted than its human counterpart but equally vital. Established in 1997 and headquartered in Northwich, Cheshire, England, Dechra has steadily made a name for itself as a formidable player addressing veterinary needs through innovative solutions and a dedication to expanding its product range. This company has built its empire by developing, manufacturing, and selling high-quality products that cater to the health of both companion animals, such as dogs and cats, and livestock. They have embedded themselves deeply into the global market, with a presence in countries across Europe, North America, and other regions, addressing therapeutic areas like endocrinology, dermatology, and anesthetics. A significant proportion of Dechra’s revenue comes through their strong partnerships and customer base spread across various veterinary practices and pet owners who rely on their trusted brands like Vetoryl and Felimazole. The company’s business model is finely tuned with a blend of regular product launches and strategic acquisitions, creating a comprehensive portfolio that keeps them ahead in the innovation curve. Not only do they supply medicine, but Dechra also invests heavily in research and development to ensure their offerings remain at the forefront of veterinary medicine. Through this, they balance between organic growth and strategic acquisitions, effectively broadening their impact in the field. This approach has not only propelled their financial success but also underscored their commitment to enhancing the welfare of animals globally.

DPH Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.3%
=
Operating Profit
24.9m
/
Revenue
761.5m
What is the Operating Margin of Dechra Pharmaceuticals PLC?

Based on Dechra Pharmaceuticals PLC's most recent financial statements, the company has Operating Margin of 3.3%.

Back to Top